Switch theme
Sign up to access all valuation multiples
Liaoning Chengda Biotechnology Co Ltd is engaged in the research and development, production and sales of human vaccines.
2002
n/a
LTM Revenue $237M
LTM EBITDA $68.1M
$701M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Liaoning Chengda Biotech has a last 12-month revenue of $237M and a last 12-month EBITDA of $68.1M.
In the most recent fiscal year, Liaoning Chengda Biotech achieved revenue of $241M and an EBITDA of $96.9M.
Liaoning Chengda Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Liaoning Chengda Biotech valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $241M | $231M | XXX | XXX | XXX |
| Gross Profit | $258M | $218M | XXX | XXX | XXX |
| Gross Margin | 107% | 94% | XXX | XXX | XXX |
| EBITDA | $96.9M | $64.8M | XXX | XXX | XXX |
| EBITDA Margin | 40% | 28% | XXX | XXX | XXX |
| Net Profit | $123M | $98.4M | XXX | XXX | XXX |
| Net Margin | 51% | 43% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Liaoning Chengda Biotech's stock price is CNY 25 (or $3).
Liaoning Chengda Biotech has current market cap of CNY 10.4B (or $1.4B), and EV of CNY 5.1B (or $701M).
See Liaoning Chengda Biotech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $701M | $1.4B | XXX | XXX | XXX | XXX | $0.12 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Liaoning Chengda Biotech has market cap of $1.4B and EV of $701M.
Liaoning Chengda Biotech's trades at 3.0x LTM EV/Revenue multiple, and 10.3x LTM EBITDA.
Analysts estimate Liaoning Chengda Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Liaoning Chengda Biotech and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $701M | XXX | XXX | XXX |
| EV/Revenue | 3.0x | XXX | XXX | XXX |
| EV/EBITDA | 10.8x | XXX | XXX | XXX |
| P/E | 31.2x | XXX | XXX | XXX |
| P/E/Growth | 1.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpLiaoning Chengda Biotech's NTM/LTM revenue growth is 9%
Liaoning Chengda Biotech's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Liaoning Chengda Biotech's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Liaoning Chengda Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Liaoning Chengda Biotech and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -4% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 28% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -33% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 37% | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 17% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 13% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 50% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| CSL | XXX | XXX | XXX | XXX | XXX | XXX |
| Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
| Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Liaoning Chengda Biotech acquired XXX companies to date.
Last acquisition by Liaoning Chengda Biotech was XXXXXXXX, XXXXX XXXXX XXXXXX . Liaoning Chengda Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Liaoning Chengda Biotech founded? | Liaoning Chengda Biotech was founded in 2002. |
| Where is Liaoning Chengda Biotech headquartered? | Liaoning Chengda Biotech is headquartered in China. |
| Is Liaoning Chengda Biotech publicy listed? | Yes, Liaoning Chengda Biotech is a public company listed on SHG. |
| What is the stock symbol of Liaoning Chengda Biotech? | Liaoning Chengda Biotech trades under 688739 ticker. |
| When did Liaoning Chengda Biotech go public? | Liaoning Chengda Biotech went public in 2021. |
| Who are competitors of Liaoning Chengda Biotech? | Similar companies to Liaoning Chengda Biotech include e.g. CSL, Imugene, Prescient Therapeutics, GSK India. |
| What is the current market cap of Liaoning Chengda Biotech? | Liaoning Chengda Biotech's current market cap is $1.4B |
| What is the current revenue of Liaoning Chengda Biotech? | Liaoning Chengda Biotech's last 12-month revenue is $237M. |
| What is the current EBITDA of Liaoning Chengda Biotech? | Liaoning Chengda Biotech's last 12-month EBITDA is $68.1M. |
| What is the current EV/Revenue multiple of Liaoning Chengda Biotech? | Current revenue multiple of Liaoning Chengda Biotech is 3.0x. |
| What is the current EV/EBITDA multiple of Liaoning Chengda Biotech? | Current EBITDA multiple of Liaoning Chengda Biotech is 10.3x. |
| What is the current revenue growth of Liaoning Chengda Biotech? | Liaoning Chengda Biotech revenue growth between 2023 and 2024 was -4%. |
| Is Liaoning Chengda Biotech profitable? | Yes, Liaoning Chengda Biotech is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
